The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, How Much Growth In Market Size Is Expected For The Fatty Liver Treatment Market?
The fatty liver treatment market size has shown significant expansion in recent years. It is projected to increase from $25.05 billion in 2025 to $26.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical growth can be linked to factors such as a rise in obesity rates, growing diabetes prevalence, improvements in liver diagnostic tools, increased awareness of liver health, and the expansion of hepatology clinics.
The fatty liver treatment market size is projected to experience significant growth in the coming years. It is expected to expand to $35.67 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is attributable to the development of novel NAFLD drugs, increased adoption of non-invasive diagnostic tools, advancements in preventive healthcare, the expansion of tele-hepatology services, and rising investment in liver disease research. Prominent trends within this period include the escalating prevalence of non-alcoholic fatty liver disease, a greater emphasis on lifestyle-based treatment approaches, the growing utilization of targeted drug therapies, the expansion of early liver disease screening initiatives, and the integration of digital health solutions for disease monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12581&type=smp
What Market Drivers Are Helping Shape The Fatty Liver Treatment Market Expansion?
The rising intake of alcohol is projected to propel the expansion of the fatty liver treatment market in the foreseeable future. Alcohol consumption refers to the ingestion of beverages containing alcohol, which is a psychoactive substance with depressant effects on the central nervous system. This consumption can exacerbate fatty liver disease and lead to more severe hepatic conditions, including alcoholic fatty liver disease (AFLD) and alcoholic hepatitis. For instance, in November 2025, according to the OECD, a Paris-based intergovernmental organization, the average per capita annual alcohol consumption across its member countries was 8.5 liters of pure alcohol in 2023. Therefore, the escalation in alcohol consumption is stimulating the growth of the fatty liver treatment market.
Which Segment-Based Categories Are Covered In The Fatty Liver Treatment Market?
The fatty liver treatment market covered in this report is segmented –
1) By Treatment Type: Anti-Viral Drugs, Chemotherapy Drugs, Targeted Therapy, Anti-Fibrotic Drugs
2) By Disease Type: Hepatitis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Other Diseases
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Subsegments:
1) By Anti-Viral Drugs: Direct-Acting Antivirals (DAAs), Nucleos(t)ide Analogs
2) By Chemotherapy Drugs: Conventional Chemotherapy Agents, Novel Chemotherapeutics Under Investigation
3) By Targeted Therapy: Small Molecule Inhibitors, Monoclonal Antibodies
4) By Anti-Fibrotic Drugs: PPAR Agonists, FXR Agonists, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Other Insulin Sensitizers
Which Trends Are Affecting The Fatty Liver Treatment Market Framework?
Leading firms within the fatty liver treatment market are prioritizing the creation of novel solutions, including advanced metabolic-modulating biologics, to address the increasing need for potent treatments that tackle the root causes of NAFLD and NASH. Such biologic therapies engage critical metabolic and inflammatory pathways, presenting a more precise and disease-altering method than conventional lifestyle interventions, which have restricted therapeutic efficacy in later disease stages. As an illustration, in March 2023, Akero Therapeutics, a US biotechnology company, announced favorable Phase II results for efruxifermin, intended for managing non-invasively diagnosed nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). This compound is a distinctive Fc-FGF21 fusion protein designed to emulate the biological function of fibroblast growth factor 21 (FGF21), a regulator of numerous metabolic pathways and cellular functions.
Which Companies Form The Competitive Landscape Of The Fatty Liver Treatment Market?
Major companies operating in the fatty liver treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd., AstraZeneca plc, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., The Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Genfit, Conatus Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Cardax Inc., Eisai Co. Ltd., Alnylam Pharmaceuticals Inc.
Access The Complete Fatty Liver Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Which Region Has The Strongest Presence In The Fatty Liver Treatment Market?
North America was the largest region in the fatty liver treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fatty liver treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Fatty Liver Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12581&type=smp
Browse Through More Reports Similar to the Global Fatty Liver Treatment Market 2026, By The Business Research Company
Liver Diseases Therapeutics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
Liver Metastases Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/liver-metastases-treatment-global-market-report
Non Alcoholic Steatohepatitis Treatment Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
